In a subanalysis of the IMPROVE-HF trial, elevated sST2 levels predicted cardiovascular-renal rehospitalizations in patients with high CA125 levels (> 35 U/mL), but not in those with CA125 ≤ 35 U/mL [21]. This evidence concerns the gene MUC16 and hydrops fetalis.